CLDN4 and pancreatic neoplasm: C-SNPs with loadings of doxorubicin (DOX-C-SNPs) collocate and target Claudin-4 in pancreatic cancer cells, disrupting TJs while being significantly reduced in normal pancreatic cells [55].